期刊文献+

咯利普兰对大鼠哮喘模型肺组织磷酸二酯酶及IL-4的影响 被引量:12

The effects of rolipram on PDE activity and IL-4 level in the lung tissue of ovalbumin sensitized and repeatedly challenged rats
下载PDF
导出
摘要 目的为阐明大鼠哮喘模型肺组织cAMP-PDE活性升高的相关原因和意义,研究了咯利普兰(rolipram,Rol)对大鼠哮喘模型的肺功能、肺组织中磷酸二酯酶(PDE)活性和IL-4含量的影响。方法采用卵白蛋白致敏后重复抗原攻击制备哮喘模型,测定肺功能,肺组织cAMP-PDE活性、PDE4的活性和IL-4含量,分类计数外周血和支气管肺泡灌洗液(BALF)中的白细胞。结果哮喘大鼠肺组织cAMP-PDE及PDE4活性与正常对照组相比均升高(P<0·05),致敏后重复抗原攻击的哮喘大鼠肺组织cAMP-PDE活性中PDE4活性比例较高,约占70%。Rol剂量依赖性增加哮喘大鼠肺顺应性,降低肺阻力,抑制增加的哮喘大鼠肺组织cAMP-PDE和PDE4活性,降低肺组织IL-4含量。以Rol(1mg·kg-1,po)作用最明显。哮喘大鼠的肺组织cAMP-PDE和PDE4活性与IL-4存在相关性(P<0·05)。此外,Rol还能明显抑制哮喘大鼠BALF中和外周血炎症细胞数目,明显抑制BALF中多形核细胞及血中EOS的比例(P<0·05)。结论致敏后重复抗原攻击的哮喘大鼠肺功能明显恶化,肺组织IL-4含量、cAMP-PDE活性明显升高,其中cAMP-PDE活性中以PDE4为主,且cAMP-PDE活性、PDE4活性与肺组织中IL-4密切相关。Rol能有效抑制哮喘大鼠肺组织cAMP-PDE及PDE4活性的升高,降低IL-4含量,改善肺功能。 Aim To illustrate the reason and significance of upregulation of cAMP-PDE activity in the lung of asthmatic rats, we studied the pulmonary function and phosphodiesterase (PDE) activity and IL-4 level in the lung tissue of model rats compared with the control rats, and observed the effects of the classical phosphodiesterase 4 inhibitor rolipram. Methods Ovalbumin sensitized and challenged rats were used as asthmatic model. Aerosol antigen induced inflammatory changes in bronchoalvelar lavegar fluid and peripheral blood were investigated. Dynamic lung compliance and pulmonary resistance were determined using a single chamber whole body plethysmogranph. Lung interleukin (IL)-4 level was determined by ELISA. cAMPPDE and PDFA activity were determined by HPLC. Results The cAMP-PDE and PDFA activity, IL-4 level and total cell counts and eosinophil counts in BALF and peripheral blood in lungs of repeatedly OA challenged and sensitized rats were singnificantly increased than those in the control rats (P 〈 0. 05 ). Meanwhile, dynamic lung compliance was singnificantly decreased and pulmonary resistance singniflcantly increased. Rolipram ( 1 mg·kg^-1, po) increased dynamic lung compliance and decreased pulmonary resistance of OA sensitized and challenged rats significantly (P 〈 0. 05 ). Rolipram significantly decreased the increased cAMP-PDE and PDFA activity in lungs of repeatedly OA challenged andsensitized rats. Rolipram (0.3 mg · kg^-1, po) and rolipram ( 1 mg · kg^-1, po) singnificantly decreased the increased IL-4 level of repeatedly OA challenged and sensitized rats (P 〈 0. 05 ). Rolipram markedly reduced total cell counts and eosinophil counts in BALF and peripheral blood of OA challenged and sensitized rats (P 〈 0. 05 ). Spearman correlation analysis showed that cAMP-PDE activity, primarily due to PDFA activity in lungs of repeatedly OA challenged and sensitized rats had statistically significant correlation with the IL-4 level (P 〈 0. 05). Conclusion Rolipram significantly increased dynamic lung compliance and decreased pulmonary resistance, decreased the increased cAMP-PDE activity and IL-4 level in lungs of repeatedly OA challenged and sensitized rats. Moreover, cAMP-PDE activity or PDFA activity had correlation with the IL-4 level.
出处 《中国药理学通报》 CAS CSCD 北大核心 2006年第4期447-451,共5页 Chinese Pharmacological Bulletin
基金 浙江省自然科学基金重点资助项目(NoZ204198)
关键词 磷酸二酯酶4 哮喘 大鼠 咯利普兰 白介素4 肺功能 高效液相色谱 肺泡灌洗液 cyclic mucleotides phosphodiesterase 4 asthma rolipram IL-4 pulmonary function HPLC bronchial alveolar lavage fluid (BALF)
  • 相关文献

参考文献17

  • 1Souness J E,Aldous D,Sargent C.Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors[J].Immunopharmacology,2000,47(2-3):127-62.
  • 2Grewe S E,Chan S C,Hanifin J M.Elevated leukocyte cyclic AMP phosphodiesterase in atopic disease:A possible mechanism for cAMP hyporesponsiveness[J].J Allergy Clin Immunol,1982,70:452-7.
  • 3Holden C A,Chan S C,Hanifin J M.Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis[J].J Invest Dermatol,1986,87:372-6.
  • 4Chan S C,Hanifin J M.Differential inhibitor effect on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes[J].J Lab Clin Med,1993,121:44-51.
  • 5Sawai T,Ikai K,Uehara M.Cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from patients with atopic dermatitis:Correlation with respiratory atopy[J].Br J Dermatol,1998,138(5):846-8.
  • 6Tenor H,Hatzelmann A,Kupferschmidt R,et al.Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages[J].Clin Exp Allergy,1995,25:625-33.
  • 7Goldberg B J,Lad P M,Ghekiere L.Phosphodiesterase activity and superoxide production in normal and asthmatic subjects neutrophils[J].J Allergy Clin Immunol,1994,93:166.
  • 8Tenor H,Hatzelmann A,Church M K,et al.Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects[J].Br J Pharmacol,1996,118:1727-35.
  • 9Gantner F,Tenor H,Gekeler V,et al.Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals:a comparative study[J].J Allergy Clin Immunol,1997,100(4):527-35.
  • 10Landells L J,Szilagy C M,Jones N A,et al.Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects[J].Br J Pharmacol,2001,133(5):722-9.

二级参考文献10

  • 1Torphy T J. Phosphodiesterase isozymes, molecular targets for novel antiasthma agents [J].Am J Respir Crit Care Med, 1998,157(2):351-370.
  • 2Chan S C, Hanifin J M.Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes [J]. J Lab Clin Med, 1993,121(1):44-51.
  • 3Giembycz M A. Phosphodiesterase 4 inhibitors and the treatment of asthma,where are we now and where do we go from here [J]? Drugs,2000,59(2):193-212.
  • 4Grewe S R,Chan Sc,Hanifin J M. Elevated leukocyte cyclic AMP phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP agonist hyporesponisiveness [J]. J Allergy Clin Immunol, 1982,70(6):452-457.
  • 5Sawai T,IKAI K, Uehara M. Cyclic adenosine mono-phosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from patients with atopic dermatitis:correlation with respiratory atopy [J]. Br J Dermatol, 1998,138(5):846-848.
  • 6Landells L J,Spina D, Souness J E,et al. A biochemical and functional assessment of monocyte phosphodies-terase activity in healthy and asthmatic subjects [J]. Pulm Pharm & Ther, 2000,13(5):231-239.
  • 7Thompson W J,Terasaki W I, Epstein P M, et al. Assay of cyclic nucleotidase phosphodiesterase and resolution of multiple molecular forms of the enzyme [J]. Adv Cyclic Nucleotide Tes, 1979,10(1):69-92.
  • 8ZHOU Han-liang, CHEN Ji-qiang, ZEN Shu, et al(周汉良,陈季强,曾苏,等). The determination of phosphodiesterase activity in leucocytes and airway smooth muscle by HPLC [J]. Chinese Pharmacological Bulletin(中国药理学通报),1995,11(4):420-423.(in Chinese)
  • 9Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding [J]. Analytical Biochemistry, 1976,72:248-254.
  • 10Kotlikoff M I, Kamm K E. Molecularmechanisms of beta-adrenergi relaxation of airway smooth muscle [J]. Annu Rev Physiol,1996,58:115-141.

共引文献2

同被引文献122

引证文献12

二级引证文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部